98%
921
2 minutes
20
Proton magnetic resonance spectroscopy is a powerful tool to investigate neurochemistry and physiology in vivo. Recently researchers have started to use MRS to measure neurotransmitter changes related to neural activity, so called functional MRS (fMRS). Particular interest has been placed on measuring glutamate changes associated with neural function, but differences are reported in the size of changes seen. This review discusses fMRS, and includes meta-analyses of the relative size of glutamate changes seen in fMRS, and the impact experimental design and stimulus paradigm may have. On average glutamate was found to increase by 6.97% (±1.739%) in response to neural activation. However, factors of experimental design may have a large impact on the size of these changes. For example an increase of 4.749% (±1.45%) is seen in block studies compared to an increase of 13.429% (±3.59) in studies using event related paradigms. The stimulus being investigated also seems to play a role with prolonged visual stimuli showing a small mean increase in glutamate of 2.318% (±1.227%) while at the other extreme, pain stimuli show a mean stimulation effect of 14.458% (±3.736%). These differences are discussed with regards to possible physiologic interpretations, as well experimental design implications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/sjop.12411 | DOI Listing |
JMIR Hum Factors
September 2025
Seidenberg School of Computer Science and Information Systems, Pace University, New York City, NY, United States.
Background: As information and communication technologies and artificial intelligence (AI) become deeply integrated into daily life, the focus on users' digital well-being has grown across academic and industrial fields. However, fragmented perspectives and approaches to digital well-being in AI-powered systems hinder a holistic understanding, leaving researchers and practitioners struggling to design truly human-centered AI systems.
Objective: This paper aims to address the fragmentation by synthesizing diverse perspectives and approaches to digital well-being through a systematic literature review.
JAMA Dermatol
September 2025
Department of Population Health, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Importance: Increasingly, strategies to systematically detect melanomas invoke targeted approaches, whereby those at highest risk are prioritized for skin screening. Many tools exist to predict future melanoma risk, but most have limited accuracy and are potentially biased.
Objectives: To develop an improved melanoma risk prediction tool for invasive melanoma.
JAMA Psychiatry
September 2025
School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
Importance: Cannabis is the most commonly used illicit drug, with 10% to 30% of regular users developing cannabis use disorder (CUD), a condition linked to altered hippocampal integrity. Evidence suggests high-intensity interval training (HIIT) enhances hippocampal structure and function, with this form of physical exercise potentially mitigating CUD-related cognitive and mental health impairments.
Objective: To determine the impact of a 12-week HIIT intervention on hippocampal integrity (ie, structure, connectivity, biochemistry) compared with 12 weeks of strength and resistance (SR) training in CUD.
JAMA
September 2025
Division of Surgery and Interventional Science, UCL, London, United Kingdom.
Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.
View Article and Find Full Text PDFJAMA Psychiatry
September 2025
Denovo Biopharma LLC, San Diego, California.
Importance: This study represents a first successful use of a genetic biomarker to select potential responders in a prospective study in psychiatry. Liafensine, a triple reuptake inhibitor, may become a new precision medicine for treatment-resistant depression (TRD), a major unmet medical need.
Objective: To determine whether ANK3-positive patients with TRD benefit from a 1-mg and/or 2-mg daily oral dose of liafensine, compared with placebo, in a clinical trial.